ENYO Pharma

Focus: ENYO Pharma is a small molecule drug developer founded in 2020 focused on infectious diseases, metabolic diseases, and oncology. The company operates as a pre-revenue biotech from Lyon, France with limited public visibility on scale.

Oncology Infectious Diseases Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About ENYO Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow ENYO Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EYP001a

Hepatitis B, Chronic

Phase 1

Clinical Trials (1)

NCT03320616EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Phase 1

Help build intelligence for ENYO Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech with exposure to three high-value therapeutic areas: oncology, infectious diseases, and metabolic diseases
Opportunity to build foundational expertise in small molecule discovery and development from early company formation
European base (Lyon, France) offers geographic diversification and access to EU regulatory pathways

Watch Out For

No active clinical programs, marketed products, or disclosed pipeline—zero clinical validation of scientific approach
Zero current job openings suggest hiring freeze or inactive recruitment despite company existence for 4+ years
No disclosed funding, financials, or revenue data raises questions about capitalization, runway, and operational sustainability

Generated by Claude from ENYO Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EYP001a

Healthy

Phase 1

Clinical Trials (1)

NCT03110276Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Phase 1

[14C]-EYP001a

Healthy

Phase 1

Clinical Trials (1)

NCT04037618Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose

Phase 1

EYP001a

NASH - Nonalcoholic Steatohepatitis

Phase 1

Clinical Trials (1)

NCT03976687Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Phase 1

EYP001a

Hepatitis B, Chronic

Phase 1

Clinical Trials (1)

NCT03272009Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

Phase 1

EYP001

Hepatitis B, Chronic

Phase 1

Clinical Trials (1)

NCT03469583Drug Drug Interaction Study for EYP001 With Entecavir

Phase 1

EYP651/Vonafexor low dose

Healthy Adult Male and Female Volunteers

Phase 1

Clinical Trials (1)

NCT07251153Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions

Phase 1

EYP001a

Hepatitis B, Chronic

Phase 2

Clinical Trials (1)

NCT04365933A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

Phase 2

Vonafexor

Alport Syndrome

Phase 2

Clinical Trials (1)

NCT06425055Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)

Phase 2

Vonafexor

Non-alcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT03812029Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)